| NCT03482401 |
Breast cancer |
Polyphenol-rich
dietary supplement containing 37 different
phenolics and 2 methylxanthines |
Inhibited breast tissue-occurring
metabolites proliferation
in p53-wild-type MCF-7 cells by inducing
cell cycle arrest, senescence, and apoptosis via p53/p21 activation |
NA/completed |
(147) |
| NCT01912820 |
Prostate cancer |
QT |
Green tea’s anticancer properties were discovered to
be enhanced by QT |
Phase I/completed |
(148) |
| NCT00949923 |
Breast cancer |
Epicatechins,
EGC, EGCG |
Polyphenols resulted in reduction in proliferation
and increase
in apoptosis post-treatment |
NA/completed |
(149) |
| NCT05758571 |
Interstitial pneumonia in cancer |
EGCG |
Exhibited pro-apoptosis, antifibrosis, anti-inflammatory,
antitumor,
and metabolic effects through modulating a variety of intracellular
signaling cascades |
Phase I/II |
(150) |
| NCT03751592 |
Squamous nonsmall
cell lung cancer |
Chlorogenic acid |
– |
Phase I/II |
(151) |
| NCT05306002 |
Breast and ovarian cancer syndrome |
– |
Following 1 to 3 months of oral supplementation,
chromosome
breakage was reduced |
NA |
(152) |
| NCT02029352 |
Melanoma |
EGCG |
Exerted cytotoxic effect on skin cancer cells, induced apoptosis,
and suppressed cell development |
Phase II/III |
(153) |
| |
|
|
EGCG inhibited catenin signaling, which is a
key component
of the WNT pathway |
|
|
| NCT01360320 |
Colorectal cancer |
EGCG |
– |
Phase II |
(154) |
| NCT01496521 |
Esophageal squamous
cell carcinoma |
Tea polyphenols |
– |
Phase III |
(155) |
| NCT02728349 |
Glioblastoma |
Chlorogenic
acid |
– |
Phase I |
(156) |
